They found that it was able to induce the upregulation of PD-L1 under interleukins (IL-1β–IL10) and TNF-α secretion, along with the inhibition of the cell-surface expression of the cytotoxic molecule TRAIL, a process dependent on the activation of the PI3K/Akt pathway.149 Moreover, in chronic lymphocytic leukaemia (CLL), the therapeutic agent trabectedin induces apoptosis of both human primary leukaemic cells, selected myeloid and lymphoid immunosuppressive cells mainly through the TRAIL/TNF pathway. Here, IL10 is linked to B-cell chronic lymphocytic leukemia.